Company: CRVO
Filing Date: 2025-04-18
Form Type: 8-K
Source: 0001437749-25-012337
Chunk: 1

Company: CervoMed Inc.
Filing Date: 2025-04-18
Form: 8-K
Item: Item 1.01
Chunk 1
---
 at Aura Biosciences (“ Aura”) from March 2021 to May 2023, overseeing regulatory affairs, chemistry, manufacturing and controls / technical operations, program and portfolio management, medical device innovation, and information technology. While at Aura, Dr. De Rosch contributed to Aura becoming a public company and growing from approximately 20 employees to approximately 65 employees to support Phase 3 readiness. Prior to joining Aura, Dr. De Rosch was Chief Regulatory Officer at Epizyme, Inc. (“ Epizyme”) where he assisted Epizyme in receiving accelerated approval in the United States (“ U. S.”) for its first drug, TAZVERIK®, in two oncology indications. Prior to Epizyme, he was Senior Vice President of Regulatory, Quality, and Medical Writing at Nightstar Therapeutics, Inc., a gene therapy company specializing in treatment of inherited retinal disease, which was acquired by Biogen in 2019. Prior organizations also include Akebia Therapeutics, Voisin Consulting Life Sciences, Inspiration Biopharmaceuticals, Vertex Pharmaceuticals (“ Vertex”), Berlex Laboratories, Diatide, and Mallinckrodt. At Vertex, Dr. De Rosch led the regulatory strategy and marketing approvals in the U. S. and European Union for Kalydeco®, the first drug to treat the underlying cause of cystic fibrosis. Dr. De ROsch has a B. S. in Chemistry/Biochemistry from the University of Wisconsin-Parkside, and an M. S. and Ph. D. in Inorganic Chemistry from the University of California, San Diego. Dr. De Rosch was designated as a Fellow of the Regulatory Affairs Professional Society (FRAPS) in 2017.

In connection with his appointment, the Company and Dr. De Rosch have entered into an Employment Agreement (the “ De Rosch Employment Agreement”) pursuant to which he will serve as our Executive Vice President, Regulatory and Government Affairs and Program Management, which is attached hereto as Exhibit 10.2. Dr. De Rosch’s annual base salary for the year ending December 31, 2025, will be $465,000 - which amount the Board may increase (but not decrease) at its discretion - and his target annual bonus will be 35 percent of her base salary. In addition, the De Rosch Employment Agreement contains certain severance and change of control provisions, non-competition and non-solicitation provisions (each applicable during employment and for 12 months thereafter